<i>In Vitro</i> and <i>In Vivo</i> Evaluation of ABCG2 (BCRP) Inhibitors Derived from Ko143
Melanie Zechner, Claudia A. Castro Jaramillo, Nadine S. Zubler, Marco F. Taddio, Linjing Mu, Karl‐Heinz Altmann, Stefanie D. Krämer
Abstract
Breast cancer resistance protein (BCRP, ABCG2) is an efflux transporter that plays a crucial role in multidrug resistance to antineoplastic drugs. Ko143, an analogue of the natural product fumitremorgin C, is a potent inhibitor of ABCG2 but is rapidly hydrolyzed to an inactive metabolite in vivo . To identify ABCG2 inhibitors with improved metabolic stability, we have assessed a series of Ko143 analogues for their ability to inhibit ABCG2-mediated transport in ABCG2 -transduced MDCK II cells and determined the stability of the most potent compounds in liver microsomes. The most promising analogues were evaluated in vivo by positron emission tomography. In vitro, three of the tested analogues were potent ABCG2 inhibitors and stable in microsomes. In vivo, they increased the distribution of the ABCG2/ABCB1 substrate [ 11 C]tariquidar to the brain both in wild-type (with Abcb1a/b transport blocked by tariquidar) and Abcb1a/b(−/−) mice. One analogue was more potent than Ko143 in both animal models.